LLY Stock Recent News
LLY LATEST HEADLINES
The Investment Committee debate the latest Calls of the Day.
"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others apply to Ken Griffin, CEO and founder of Citadel.
AbbVie Inc. entered the obesity market by in-licensing GUBamy, a long-acting amylin analog, a modest but important first step to challenge Eli Lilly and Novo Nordisk. AbbVie's will pay $350 million upfront for GUBamy, with potential milestones up to $1.875 billion, and royalties on net sales. Amylin analogs like GUBamy offer promising weight loss effects (albeit not at the levels of leading incretin therapies), with potentially much better GI tolerability, lean mass preservation and cardiovascular safety.
The Investment Committee give you their top stocks to watch for the second half.
U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, with both citing increased threats after a UnitedHealth insurance executive was murdered outside the company's investor meeting in December, regulatory filings show.
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Like many pharma stocks, Eli Lilly (LLY -4.58%) offers investors a bit of safety -- and it's an element you can count on during any economic environment. This is because patients need their medicines and will continue to order them through good times and more difficult times as well.
Eli Lilly (LLY -4.58%) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of their value during the big market sell-off that day, and it wasn't only because of the general gloom.
Eli Lilly and Company (NYSE:LLY ) Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ET Company Participants Lucas Montarce - CFO Mike Czapar - Head of IR Conference Call Participants Dave Risinger - Leerink Partners Dave Risinger All right. So, I think we should get started here.
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.